Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Sagent Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
A.forall Launches Fifth ANDA and Second “First Cycle” FDA Approval
Details : A generic version of Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.
Brand Name : Precedex-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2024
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Sagent Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?